Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status
Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos
GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers